RxDoctor Payments Data

David Folk

Family · Pittsburgh, PANPI 1265800718

Payments from drug & device makers

$3,240in general payments, 2019–2025

Across 163 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$431
  • Ardelyx, Inc.$431
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$359
  • Phathom Pharmaceuticals, Inc.$277
  • Bristol Myers Squibb$260
  • plus $415 from 10 others

What the payments were for

  • Food & beverage$3,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,240 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,341
Medicare patients
283
Services billed
310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine147$84,693
XifaxanRifaximin20$60,670
LinzessLinaclotide78$54,953
MovantikNaloxegol Oxalate23$10,011
TrulancePlecanatide17$9,249
Pantoprazole Sodium925$8,881
Dexlansoprazole DrDexlansoprazole27$8,017
Mesalamine ErMesalamine12$6,750
Colestipol Hcl127$6,551
Famotidine450$4,440
Omeprazole379$3,893
Sucralfate104$2,858
Diltiazem 12hr ErDiltiazem Hcl11$2,477
Colesevelam Hcl54$2,348
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$359$69,91937 claims
AbbVieLinzess$1,068$54,95378 claims
Braintree Laboratories, Inc.Sutab$37$2,17714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →